home / stock / veru / veru news

VERU News and Press, Veru Inc.

Stock Information
Company Name: Veru Inc.
Stock Symbol: VERU
Market: NASDAQ
Website: veru.de
Menu
VERU VERU Quote VERU Short VERU News VERU Articles VERU Message Board
Get VERU Alerts

News, Short Squeeze, Breakout and More Instantly...
VERU - Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Ste...
VERU - Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced tha...

VERU - Veru GAAP EPS of -$0.07 misses by $0.01, revenue of $4.14B beats by $4.14B

2024-05-08 06:33:25 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru Q2 2024 Earnings Preview Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earning...

VERU - Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical,...
VERU - Veru Q2 2024 Earnings Preview

2024-05-07 12:06:40 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial info...

VERU - VERU Price Target Alert: $3.00. Issued by H.C. Wainwright

2024-05-03 14:00:03 ET Yi Chen from H.C. Wainwright issued a price target of $3.00 for VERU on 2024-05-03 11:38:00. The adjusted price target was set to $3.00. At the time of the announcement, VERU was trading at $1.67. The overall price target consensus is at $11.50 wit...

VERU - Veru to Present at the GLP-1 Based Therapeutics Summit

MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced tha...
VERU - Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it ...

VERU - Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ...

VERU - Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced t...
Next 10